リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Cumulative Incidences of Lung Cancer in Various Interstitial Lung Diseases

Takafumi Suzuki Tsukasa Okamoto Masako Akiyama Takayuki Honda Masaru Ejima Masahiro Ishizuka Hiroyuki Sakashita Yasunari Miyazaki 東京医科歯科大学 DOI:10.11480/jmds.690002

2022.11

概要

Introduction: Interstitial lung disease (ILD) patients often develop lung cancer (LC). However, previous studies on the incidences of LC in ILDs focused on specific aetiologies, such as idiopathic pulmonary fibrosis (IPF). To investigate the incidences of LC in ILDs other than IPF, we conducted this study. Materials and Methods: ILD patients at our hospital were retrospectively reviewed. The cumulative incidences of LC in various ILD patients were estimated and compared among ILD groups for up to five years. The association between several variables at initial diagnosis and LC development was assessed to identify predictors. Results: In all, 587 ILD patients, including 161 IPF, 160 chronic HP, 133 non-IPF idiopathic interstitial pneumonias (IIPs), 87 connective tissue disease-related ILDs (CTD-ILDs), and 46 other ILDs, were included. Twenty-seven patients developed LC. The cumulative incidences of LC at 1, 3, and 5 years were 1.9%, 5.7%, and 12.3% in IPF, respectively; 2.0%, 4.6%, and 11.0% in chronic HP; 0.8%, 0.8%, and 4.0% in non-IPF IIPs; and 1.1%, 1.1%, and 2.9% in CTD-ILDs. Chronic HP patients had a high incidence of LC as IPF patients. Pack-years was associated with LC development in chronic HP patients. Conclusions: The incidences of LC are equally high in patients with chronic HP and IPF.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68.

2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evi- dence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824.

3. Travis WD, Costabel U, Hansell DM, et al. An official Amer- ican Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48.

4. Panos RJ, Mortenson RL, Niccoli SA, et al. Clinical dete- rioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990; 88(4):396-404.

5. Raghu G, Amatto VC, Behr J, et al. Comorbidities in idio- pathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015; 46(4):1113-30.

6. Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryp- togenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161(1):5-8.

7. Le Jeune I, Gribbin J, West J, et al. The incidence of can- cer in patients with idiopathic pulmonary fibrosis and sar- coidosis in the UK. Respir Med. 2007; 101(12):2534-40.

8. Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5):723-8.

9. Hyldgaard C, Hilberg O, Bendstrup E. How does comor- bidity influence survival in idiopathic pulmonary fibrosis? Respir Med. 2014; 108(4):647-53.

10. Kwak N, Park CM, Lee J, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphy- sema. Respir Med. 2014; 108(3):524-30.

11. Kim ES, Choi SM, Lee J, et al. Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis. Chest. 2015; 147(2):430-7.

12. Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015; 147(1):157-64.

13. Portillo K, Perez-Rodas N, Garcia-Olive I, et al. Lung Can- cer in Patients With Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis. A Descrip- tive Study in a Spanish Series. Arch Bronconeumol. 2017; 53(6):304-10.

14. Choi WI, Park SH, Park BJ, et al. Interstitial Lung Dis- ease and Lung Cancer Development: A 5-Year Nation- wide Population-Based Study. Cancer Res Treat. 2018; 50(2):374-81.

15. Kato E, Takayanagi N, Takaku Y, et al. Incidence and pre- dictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018; 4(1).

16. Miura Y, Saito T, Tanaka T, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018; 56(1):72-9.

17. Yoo H, Jeong BH, Chung MJ, et al. Risk factors and clini- cal characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2019; 19(1):149.

18. Lee KJ, Chung MP, Kim YW, et al. Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis. Thorac Cancer. 2012; 3(2):150-5.

19. Enomoto Y, Inui N, Yoshimura K, et al. Lung cancer devel- opment in patients with connective tissue disease-related interstitial lung disease: A retrospective observational study. Medicine (Baltimore). 2016; 95(50):e5716.

20. Choi WI, Lee DY, Choi HG, et al. Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide popu- lation-based study. Respir Res. 2019; 20(1):117.

21. Kuramochi J, Inase N, Miyazaki Y, et al. Lung cancer in chronic hypersensitivity pneumonitis. Respiration. 2011; 82(3):263-7.

22. Yoshizawa Y, Ohtani Y, Hayakawa H, et al. Chronic hypersensitivity pneumonitis in Japan: a nationwide epi- demiologic survey. The Journal of allergy and clinical immunology. 1999; 103(2 Pt 1):315-20.

23. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism col- laborative initiative. Arthritis Rheum. 2010; 62(9):2569-81.

24. Preliminary criteria for the classification of systemic scle- rosis (scleroderma). Subcommittee for scleroderma crite- ria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90.

25. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). The New England journal of medicine. 1975; 292(7):344-7. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. The Journal of investigative dermatology. 1993; 100(1):124S-7S.

26. Shiboski SC, Shiboski CH, Criswell LA, et al. American Col- lege of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis care & researchArthritis Care Res (Hobo- ken). 2012; 64(4):475-87.

27. Petri M, Orbai A-M, Alarcón GS, et al. Derivation and val- idation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythema- tosus. Arthritis Rheum. 2012; 64(8):2677-86.

28. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51.

29. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Trans- plant. 2013; 48(3):452-8.

30. De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Cen- tre Cohort Study. J Clin Med. 2018; 8(1).

31. Salisbury ML, Gu T, Murray S, et al. Hypersensitivity Pneu- monitis: Radiologic Phenotypes Are Associated With Dis- tinct Survival Time and Pulmonary Function Trajectory. Chest. 2019; 155(4):699-711.

32. Sobiecka M, Szturmowicz M, Lewandowska K, et al. Chronic hypersensitivity pneumonitis is associated with an increased risk of venous thromboembolism: a retro- spective cohort study. BMC Pulm Med. 2021; 21(1):416.

33. Invernizzi R, Wu BG, Barnett J, et al. The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021; 203(3):339-47.

34. Kang J, Kim YJ, Choe J, et al. Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and out- comes. Respir Res. 2021; 22(1):152.

35. Hanak V, Golbin JM, Hartman TE, et al. High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest. 2008; 134(1):133-8.

36. Silva CI, Müller NL, Lynch DA, et al. Chronic hypersensitiv- ity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT. Radiology. 2008; 246(1):288-97.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る